Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Incorporate a hardware wallet into your security plan, plus complementary practices to reduce exposure and strengthen protection.
19,201 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
An investor group disclosed a $3.5 million stake in Avantor as the stock slipped more than half. This article breaks ...
Investors eyeing a $70,000 annual payout from investments are weighing dividend ETFs and fixed income. This guide bre...
New FEC filings show NAR's RPAC spent more than $10 million across campaigns and committees in 2025-26, with notable ...
JPMorgan CEO Jamie Dimon argues the United States is drifting toward Europe’s slower defense model, calling for priva...
Raymond James raises Marathon's target to 270, driven by sustained refining margins and strong MPLX distributions. MP...
What would it look like if a legendary duo concentrated nearly $80 billion into one stock? This thought-provoking pie...
Lucid Diagnostics (LUCD) is navigating reimbursement and adoption as it scales its non-invasive tests. This analysis ...
Anchorage Digital is introducing institutional custody for TRX, a regulatory milestone that could reshape near-term p...
Macy’s just rolled out an AI-powered shopping assistant across its online and app platforms. Early data show engaged ...
Multicoin Capital disclosed a substantial Zcash position, triggering a double-digit rally in ZEC. The move underscore...
NWN’s Q1 2026 results reveal how the company balances growth with profitability. This analysis breaks down the number...